In a report released yesterday, Josh Jennings from TD Cowen maintained a Buy rating on Avita Medical, with a price target of $5.50.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Josh Jennings has given his Buy rating due to a combination of factors related to Avita Medical’s emerging wound care platform. He views the recently presented interim Cohealyx-I data as a strong indicator that Cohealyx can materially shorten the time to grafting for severe burn patients compared with established real‑world outcomes, with results that are both clinically meaningful and statistically robust.
The positive physician feedback from key burn surgeons, including high satisfaction levels among largely first‑time users, further reinforces his conviction that Cohealyx will occupy an important role within Avita’s broader wound care ecosystem. Jennings expects that continued favorable trial readouts and growing clinician adoption across the company’s three-product portfolio will translate into sustained commercial momentum, supporting a positive outlook for RCEL shares.
Jennings covers the Healthcare sector, focusing on stocks such as Boston Scientific, TransMedics Group, and Abbott Laboratories. According to TipRanks, Jennings has an average return of 1.9% and a 44.69% success rate on recommended stocks.